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Background: Epidemiological studies revealed a strong correlation between the metabolic syndrome/diabetes
mellitus type 2 (DM2) and higher incidence and faster progression of breast and colon cancer. However, the
underlying molecular mechanisms are widely unknown. Akt and phospholipase Cγ (PLCγ) are involved in tyrosine
kinase signaling and promote tumor cell growth and migration. Therefore, we examined regulatory functions and
expression of Akt and PLCγ in a simplified in vitro diabetogenic model.
Findings: Protein expression was determined by western blot analysis in MDA-MB-468 breast cancer and SW480
colon cancer cells previously cultured under physiologic (5.5 mM) and diabetogenic (11 mM) glucose
concentrations (without and with 100 ng/ml insulin). We studied the culture effects on proliferation and migration
of these cells, especially after inhibiting Akt and PLCγ. We found that Akt expression was up-regulated with high
glucose and insulin in both cell lines, whereas PLCγ expression was enhanced in colon cancer cells only. High levels
of glucose and insulin increased cell proliferation and migration in both cell lines in vitro, mediated by Akt and
PLCγ, as shown through the specific pharmacological inhibitors A6730 and U73122.
Conclusions: Our molecular data explain glucose- and insulin-induced changes in a cancer cell and help to
understand what might trigger tumor cell proliferation and migration in DM2 patients, too.
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Breast cancer is the most common type of cancer in
women, and colon cancer is the third most common can-
cer in both sexes and the second leading cause of cancer
deaths worldwide [1]. The majority of cancer patients,
however, will not decease because of their primary tumor,
but rather because of the spreading of metastasis, which is
responsible for over 90% of cancer deaths [2].* Correspondence: nicola.tomas@uni-wh.de
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reproduction in any medium, provided the orThe prevalence of obesity has increased dramatically
over the last four decades, and it can be considered the
leading health problem of the developed countries in the
21st century. Obesity is strongly associated with the devel-
opment of diabetes mellitus type 2 (DM2) and co-morbid
diseases, such as hypertension and hyperlipidemia, com-
monly summarized as the metabolic syndrome [3].
Up-to-date retrospective and prospective epidemiological
studies showed strong correlations between the metabolic
syndrome and the incidence of malignant neoplasms
in different organs [4,5]. Obesity increases the risk of
breast and colon cancer [6,7]. DM2 is directly associated
with a higher incidence and faster progression of several
neoplasms including colon and breast cancer [5,8]. InLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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commonly found in DM2 patients, seem to increase the
risk for breast and colon cancer [9,10]. Besides, tyrosine
kinases, namely the insulin receptor (IR) and insulin-like
growth factor (IGF) receptors, are over-expressed in
several human cancers, including cancer of the breast
[11]. Consequently, over-expression of these receptors
yields a selective growth advantage to breast cancer
cells, especially in the presence of insulin resistance and
associated hyperinsulinemia [12]. It has been known for
over two decades that glucose is the driving force for
tumor cell growth [13] and that high levels of insulin
promote metastasis [14].
Insulin operates by binding to its target cell receptor, a
heterotetrameric, transmembrane, multisubunit glyco-
protein. The insulin signal is propagated through a phos-
phorylation network involving intracellular molecules
such as phosphoinositid-3-kinase (PI3K), protein kinase
B (PKB, Akt) and phospholipase Cγ (PLCγ). The serine/
threonine kinase Akt is a well known regulator of widely
divergent cellular processes, and it is implicated in intra-
cellular insulin signaling. Akt has been described as an
oncogene in several human cancers [15,16], and it is
known to be a promoter of tumor cell proliferation [17],
prolonged cell survival [18,19], and angiogenesis [20].
The phosphorylation and thus activation of Akt can be
specifically inhibited by the trifluoroacetate salt hydrate
A6730 [21]. Phospholipases (PLCs) are tyrosine kinase
substrates that provide diacylglycerols (DAGs) for intra-
cellular signaling in various contexts and its isoform
PLCγ is known to be implicated in intracellular insulin
signaling [22] and in colon and breast cancer progression
[23,24]. U73122 is an aminosteroid that specifically inhi-
bits PLCγ activation [25].
Given this knowledge about the gravity of glucose me-
tabolism in tumor cells on the one hand and the growing
number of studies investigating the epidemiological con-
nection between the metabolic syndrome/DM2 and the
development and progression of several human cancers on
the other hand, surprisingly little is known about the
underlying molecular changes and mechanisms that facili-
tate tumor development and progression when excessive
glucose and insulin are available.
For these reasons, we report about the regulatory func-
tions of Akt and PLCγ regarding tumor cell proliferation
and migration under the specific premise of higher than
normal glucose and insulin concentrations.
Methods
Cell culture
For all experiments the tumor cell lines SW480 colon
adenocarcinoma and MDA-MB-468 mammary gland
adenocarcinoma (both American Type Culture Collection,
Manassas, VA, USA) were kept in RPMI 1640 mediasupplemented with 10% fetal bovine serum (PAA Labora-
tories, Pasching, Austria) and 1% penicillin/streptomycin
(PAN Biotech GmbH, Aidenbach, Germany). The medium
contained either 5.5 mM (99.1 mg/dl) glucose, 11 mM
(198.2 mg/dl) glucose, or 11 mM glucose plus 100 ng/ml
insulin. All cells were incubated at 37°C humidified atmos-
phere and 5% CO2 (Binder, Tuttlingen, Germany).
Western blot analysis
The expression levels of Akt and PLCγ were analyzed by
immunoblotting as described previously [26]. Cells (1 × 106)
were lysed in Laemmli sample buffer and incubated for
10 min at 95°C. Proteins were separated using SDS-PAGE
and transferred to an PVDF-Immobilion-P membrane
(Millipore, Schwalbach, Germany), followed by blocking
with 10% milk powder (1 h at room temperature (RT)).
After incubating the membrane overnight at 4°C with
the primary monoclonal antibodies against Akt (Cell
Signaling Technology, Boston, USA) and PLCγ (Sigma-
Aldrich, Deisenhofen, Germany), membrane were washed
vigorously with PBS-Tween. Subsequently, the membrane
was incubated with appropriate anti-mouse or anti-goat
peroxidase-linked secondary antibodies for 1 h at RT (all
Southern Biotech, Birmingham, AL, USA), followed by
incubation with the chemiluminescence blotting sub-
strate (Roche Diagnostics, Mannheim, Germany) for
1 min at RT for visualization. Bands were detected using
the Aequoria Macroscopic Imaging System (Hamatsu,
Herrsching am Ammersee, Germany) and quantified using
Wasabi 1.4 software (Hamatsu, Herrsching am Ammersee,
Germany). The numbers shown are expressed as percen-
tages of the 5.5 mM glucose control condition.
Cell proliferation assay
Proliferation analysis was performed in a 96-well-plate
with 104 cells per well. Cells were incubated for 48 h at
37°C humidified atmosphere and 5% CO2 with and with-
out the inhibitors A6730 and U73122 in a concentration
of 500nM and 500 mg/dl, respectively (both Sigma-
Aldrich, Deisenhofen, Germany). Then, according to the
manual, 25μl of MTS color solution (Promega, Madison,
WI, USA) was added directly to the culture wells and
cells were then incubated under the same conditions for
2 h. Absorbance of the resulting colored formazan prod-
uct was recorded at 490 nm in a 96-well-plate-reader.
The quantity of formazan product is directly propor-
tional to the number of living cells in culture.
Cell migration assay
Cell migration was assessed using a three-dimensional
collagen matrix assay followed by computer-assisted cell
tracking [27]. A liquid collagen solution (purified collagen,
Inamed Biomaterials, Fremont, CA, USA) was mixed with
10x MEM (Sigma, Taufkirchen, Germany), 7.5% sodium
(A) (B)
Figure 1 Western blot analysis of Akt and PLCγ expression.
Western blot analysis was performed to evaluate Akt and PLCγ
expression and shows that Akt expression was up-regulated in both
cell lines when additional glucose was available (A). The combination
of glucose and insulin caused an even higher up-regulation in both
cell lines (A). PLCγ expression showed considerable increase in SW480
colon cancer cells exclusively (B). Numbers indicate relative Akt and
PLCγ expression levels in relation to β-actin, whereby expression levels
in the 5.5 mM glucose control media were set to 100%.
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cells to be analyzed, and the inhibitors A6730 (500nM)
and U73122 (500 ng/ml). Cell migration within the three-
dimensional collagen matrix was recorded for 10 h at 37°C
by time-lapse video-microscopy and subsequently ana-
lyzed by computer-assisted cell tracking. For analysis of
the migratory activity, 30 cells per sample were randomly
selected and paths were digitized as x/y coordinates in
15 min intervals. Migratory activity (MA) refers to the
percentage of cells moving during a particular 15 min
interval, and average migratory activity (AMA) is the
average percentage of moving cells, calculated from all
15 min intervals in a 10 h period. Thereby, 100% MA
was reached when all 30 cells migrated during the corre-
sponding 15 min interval and 100% AMA was reached
when all 30 cells migrated constantly over 10 h. The
average distance migrated (ADM) in μm was calculated
from 10 h of analysis.
Statistical analysis
Data is presented as mean and standard deviation. Statistical
significance was determined by Student’s t-test, whereby
p< 0.05 was considered significant. All experiments were
performed 3–6 times.
Findings
To analyze Akt/PLCγ expression, proliferation capacity,
and cell migration we cultured different tumor cell lines
(MDA-MB-468 breast and SW480 colon cancer cells) at
physiological (5.5 mM, control) and diabetogenic (11 mM)
glucose concentrations without and with 100 ng/ml insulin.
Raising the glucose concentration from 5.5 mM to
11 mM increased the expression of Akt by 23% in MDA-
MB-468 breast cancer cells (Figure 1A). Addition of
100 ng/ml insulin to the 11 mM culture media increased
Akt expression by another 6% when compared to cells
cultured with 11 mM glucose alone. An even stronger
effect could be seen for SW480 colon cancer cells, which
raised Akt expression by 52% when cultured with high
glucose concentrations. Here adding 100 ng/ml insulin
caused a further increase of 14% (to 66%). The Akt-
enhancing effect of insulin can be quantified as approxi-
mately one fourth of the glucose effect in both cell lines.
MDA-MB-468 cells did not significantly up-regulate
phospholipase Cγ (PLCγ) expression neither when kept
under higher than normal glucose concentrations alone,
nor when 100 ng/ml insulin was added (Figure 1B). In
SW480 cells high glucose and insulin levels showed an
increase in PLCγ expression of 27% each, leading to a
total increase of 54%.
We performed a proliferation assay in order to
analyze the influence of both, high glucose and insulin
concentrations, as well as inhibition of Akt and PLCγ
on the proliferative capacity of the two tumor cell lines(Figure 2). In this assay, absorbance values at 490 nm
are directly proportional to the number of living cells
in culture. Both cell lines revealed significantly higher
proliferation rates when cultured with additional insulin
and hyperglycemic glucose concentrations. Thereby, cells
stimulated with glucose (11 mM) had similar proliferation
rates to cells stimulated with insulin alone (p = 0,2). Pro-
liferation was highest when cells were simultaneously
stimulated with glucose and insulin. Furthermore, inhib-
ition of Akt and PLCγ by A6730 and U73122, respect-
ively, reduced proliferative activity significantly when
compared to glucose- and insulin-stimulated cell prolif-
eration (Figure 2). On the other hand, no significant
effect on tumor cell proliferation was seen after adding
A6730 and U73122 to the control media (data not
shown). SW480 cells displayed significantly higher pro-
liferation rates than MDA-MB-468 cells when kept under
normal and increased glucose and insulin concentrations













































Figure 2 Tumor cell proliferation with high glucose and insulin.
MDA-MB-468 breast cancer and SW480 colon cancer cells
significantly increased proliferation rates after addition of insulin
(100 ng/ml) and doubling glucose concentrations. Even higher
proliferative capacity was seen when cells were simultaneously
stimulated with glucose and insulin. SW480 cells showed
consistently higher proliferation rates than MDA-MB-468 cells.
Addition of AKT-inhibitor A6730 and PLCγ-inhibitor U73122
significantly reduced tumor cell proliferation to levels comparable
with the control. P-values reflect 5.5 mM glucose plus insulin and
11 mM glucose against control, 11 mM glucose plus insulin against
11 mM glucose, and both culture conditions including the inhibitors
against 11 mM glucose plus insulin. Thereby, *p <0.05; **p< 0.001;
***p< 0.0001.
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increased migratory activity (MA) in the investigated cell
lines. MA refers to the percentage of cells moving during a
partiular 15 min interval. Akt-inhibitor A6730 and PLCγ-
inhibitor U73122 significantly reduced MA in both cell
lines (Figure 3A). This glucose- and insulin-induced in-
crease in cell migration is also reflected by an augmenta-
tion in average migratory activity (AMA), i.e. the average
percentage of moving cells, calculated from all 15 min
intervals in a 10 h period (Figure 3B). Maximum MA in
MDA-MB-468 and SW480 cell lines was seen after con-
current stimulation with 11 mM glucose and 100 ng/ml
insulin. It could be observed that both cell lines achieved
this increase in MA by longer episodes of migration and
shortening of pauses. Both inhibitors were able to annihi-
late the stimulating effect of insulin. Thereby, addition of
U73122 resulted in migratory levels comparable to cells
that were stimulated by a high level of glucose alone
(11 mM) and thus only abolished the inducing effect of
insulin. In comparison, A6730 reduced migration even
below the control condition (5.5 mM) in both cell lines
(Figure 3B).
The fact that glucose and insulin were strong inducers
of tumor cell migration is also reflected by an increase in
average distance migrated (ADM, Figure 3C). ADM refersto the average distance in μm that a cell covered during
10 h of analysis. Both, glucose and insulin, significantly
elongated ADM, regardless of the cell type. Cells that
were exposed to one of the inhibitors significantly reduced
ADM when compared to cells cultured with 11 mM glu-
cose and 100 ng/ml insulin. A6730 reduced ADM to a
greater extent than U73122 in both cell lines (Figure 3C).
Both inhibitors showed no significant effects on migratory
parameters when added to the control media (data not
shown).
Regarding the distance migrated over 10 h, MDA-MB-
468 breast cancer cells appear to be more susceptible to
glucose- and insulin-stimulation than SW480 colon cancer
cells (p< 0.05 for 11 mM glucose, p< 0.001 for 11 mM
glucose plus insulin). We observed that this effect was due
to a greater augmentation in migratory velocity.
Discussion
Tumor staging – including tumor size and invasiveness,
lymphatic tissue involvement, and spreading to distant
organ sites – is the main predictor of the prognosis for
most solid organ tumor patients. Thus, finding bio-
chemical signatures that define a tumor’s potential to
metastasize can build the basis for new ways of deter-
mining a patient’s prognosis and eventually lead to new
therapeutic targets. Glucose metabolism and its regula-
tion, i.e. transcellular glucose transport and hormonal
control via insulin and modification of the following sig-
naling pathways, are such possible signatures. The results
presented in this work strongly suggest that the glucose-
and insulin-induced changes in proliferation and migra-
tion of MDA-MB-468 breast cancer and SW480 colon
cancer cells are mediated by changes in Akt and/or PLCγ
signaling. The investigated cell lines are widely used in
cancer research and are well characterized in the context
of their metabolic response to increased availability of glu-
cose and insulin [28,29].
Akt is activated in most tumors [30] and various onco-
genic functions, such as induction of migration [31] and
metastasis [32], proliferation [17], and prolonged cell sur-
vival [18], have been described. Interestingly, Akt also
enhances cellular glucose uptake by mobilizing glucose
transporters to the cell surface [33]. In 2010, Johnson et al.
[34] showed that proteins of the phosphoinositid-3-kinase
(PI3K)/Akt pathway are significantly over-expressed in
colorectal cancer compared to healthy cells, and that ex-
pression levels correlated with cancer stage. PI3K is acti-
vated by tyrosine kinase receptor stimulation, especially by
the binding of insulin [35]. PI3K mediates the generation
of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) which
allows Akt to be phosphorylated and thus activated [36].
The increased expression of Akt that we found with high
glucose and insulin provides augmented substrate for the
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Figure 3 Tumor cell migration with high glucose and insulin. MDA-MB-468 breast cancer and SW480 colon cancer cells reduced migratory
activity (MA) after addition of Akt-inhibitor A6730 and PLCγ-inhibitor U73122 when compared to cells stimulated with increased glucose and
insulin (A). MA is the percentage of cells moving at a particular 15 min interval. Both cell lines significantly increased average migratory activity
(AMA, B) and average distance migrated (ADM, C) after stimulation with glucose and insulin. AMA is the average percentage of moving cells,
calculated from all 15 min intervals in a 10 h period. ADM refers to the average distance in μm that a tumor cell covered during 10 h of analysis.
Akt-inhibitor A6730 and PLCγ-inhibitor U73122 significantly reduced AMA and ADM when compared to cells stimulated with increased glucose
and insulin, emphasizing the regulatory functions of Akt and PLCγ when glucose and insulin concentrations are high. P-values reflect 5.5 mM
glucose plus insulin and 11 mM glucose against control, 11 mM glucose plus insulin against 11 mM glucose, and both culture conditions
including the inhibitors against 11 mM glucose plus insulin. Thereby, *p< 0.05; **p< 0.001; ***p< 0.0001.
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lated by glucose and insulin. The fact that addition of the
Akt-specific inhibitor A6730 markedly decreased cell mi-
gration and proliferation with high glucose and insulin
emphasizes that the up-regulation of Akt plays a crucial
role in the processes of proliferation and migration. We
could also show that the inhibitory effects of A6730 were
specific to the setting with high glucose and insulin as no
inhibitory effects of A6730 were evident when used with-
out simultaneous stimulation by glucose and insulin.
In breast cancer patients, PLCγ was shown to be up-
regulated in distant metastases when compared with the
primary tumor, indicating its involvement in metastasis
formation [23]. In our experiments, increased glucose
and insulin caused an up-regulation of PLCγ in SW480
colon cancer cells, but no up-regulation in MDA-MB-
468 breast cancer cells. However, migration and prolif-
eration could be reduced significantly by adding U73122
to the diabetic culture conditions. This highlights the
regulating capacity of PLCγ in both cell types. Thereby,
the inhibitory effect of U73122 was specific to thecondition with increased glucose and insulin as no de-
crease in proliferation and migration was seen when
U73122 was used with normal glucose and no insulin.
How the treatment of diabetes is linked to the inci-
dence of several cancers has gained a lot of interest over
the last years and alarming data has recently been pub-
lished. Hemkens et. al. [37] found that patients treated
with human insulin or insulin analogues had a higher in-
cidence of malignant neoplasms than patients who were
not treated with insulin. Furthermore, the risk of devel-
oping cancer increased with higher dosages of insulin.
In 2010, Baur et al. [38] stated that among diabetic
patients, those treated with insulin had a four-fold
higher risk to die from cancer. However, patients treated
with the insulin-sensitizing antidiabetic agent metformin
had mortality levels comparable with those of non-dia-
betic patients. Our in vitro results support these findings
and help to explain how insulin and insulin therapy may
increase cancer progression: from our point of view, in-
sulin is a strong inducer of tumor cell migration and
proliferation and a promoter of oncogenes such as Akt
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a family history for cancer, the use of long-acting insulin
in the treatment of DM2 should be reconsidered.
Conclusions
Our data show how glucose and insulin change prolifera-
tion and migration capacity in MDA-MB-468 breast can-
cer and SW480 colon cancer cells in vitro. Our results help
to understand the diverse roles of glucose and insulin –
energy supply and modulation of signaling cascades by
modifying Akt and PLCγ expression – and thus explain
which changes on a molecular, transcriptional level could
be responsible for the epidemiological connection between
the metabolic syndrome/DM2 and the progression of vari-
ous malignancies. Considering our findings regarding the
essential role of Akt in tumor progression, pharmaco-
logical research targeting this oncogene might be particu-
larly promising.
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